Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
Lumicera Secures Purchase Agreement for Stelara® Biosimilar, Delivering Major Cost Savings [Yahoo! Finance]
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target lowered by analysts at Bank of America Co. from $23.00 to $20.00. They now have a "buy" rating on the stock.
United States Lidocaine Patches Market Report 2024 with Long-term Outlook, Competitive Landscape of Amneal, Endo, Hisamitsu, Medline, Scilex, Sparsha, Teikoku, Teva, Viatris, and YARAL [Yahoo! Finance]